EA200300558A1 - Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы - Google Patents

Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы

Info

Publication number
EA200300558A1
EA200300558A1 EA200300558A EA200300558A EA200300558A1 EA 200300558 A1 EA200300558 A1 EA 200300558A1 EA 200300558 A EA200300558 A EA 200300558A EA 200300558 A EA200300558 A EA 200300558A EA 200300558 A1 EA200300558 A1 EA 200300558A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
substituted
unsubstituted
cycloalkyl
group selected
Prior art date
Application number
EA200300558A
Other languages
English (en)
Other versions
EA006920B1 (ru
Inventor
Натан Брайан Мантло
Айван Колладо Кано
Сэмьюэл Джеймс Доминианни
Гаррет Джей мл. Этджен
Кристина Гарсиа-Паредес
Ричард Дуэйн Джонстон
Майкл Эдвард Летурно
Майкл Джон Мартинелли
Дэниэл Рей Мэйхью
Ашраф Саиид
Ричард Крейг Томпсон
Ксиадонг Ванг
Дэвид Скотт Коффи
Кристофер Рэндэлл Шмид
Джеффри Томас Виченци
Янпинг Ксу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200300558A1 publication Critical patent/EA200300558A1/ru
Publication of EA006920B1 publication Critical patent/EA006920B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cultivation Of Plants (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к соединениям, представленным следующей структурной формулой, их фармацевтически приемлемым солям, сольватам и гидратам, где R1 означает замещенную или незамещенную группу, выбираемую из C-Cалкила, арил-Cалкила, гетероарил-Cалкила, Cциклоалкиларил-Cалкила или фенила. W означает O или S. R2 означает H, замещенную или незамещенную группу, выбираемую из C-Cалкила, C-Cциклоалкила и гетероарила. X означает C-Cалкиленовое связующее звено, в котором один атом углерода может быть заменен O, NH или S. Y означает C, O, S, NH или простую связь. E означает (CH)COOH, где n равно 0, 1, 2 или 3, или C(R3)(R4)A, где A означает кислотную функциональную группу, такую как карбоксил, карбоксамид, замещенный или незамещенный сульфонамид, замещенный или незамещенный тетразол. R3 означает H, насыщенный или ненасыщенный C-Cалкил, C-Cалкокси. Кроме того, R4 означает H, галоген, замещенную или незамещенную группу, выбираемую из C-Cалкила, C-Cалкокси, C-Cциклоалкила, арил-C-Cалкила и фенила, либо R3 и R4 соединены с образованием C-Cциклоалкила.Отчет о международном поиске был опубликован 2003.05.01.
EA200300558A 2000-11-10 2001-11-09 Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы EA006920B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10
PCT/US2001/042928 WO2002038553A2 (en) 2000-11-10 2001-11-09 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists

Publications (2)

Publication Number Publication Date
EA200300558A1 true EA200300558A1 (ru) 2004-02-26
EA006920B1 EA006920B1 (ru) 2006-04-28

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300558A EA006920B1 (ru) 2000-11-10 2001-11-09 Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы

Country Status (35)

Country Link
US (3) US7304062B2 (ru)
EP (1) EP1335908B1 (ru)
JP (1) JP4243101B2 (ru)
KR (1) KR100839705B1 (ru)
CN (1) CN1479728A (ru)
AR (1) AR031305A1 (ru)
AT (1) ATE386026T1 (ru)
AU (3) AU2859202A (ru)
BR (1) BR0114986A (ru)
CA (1) CA2421154A1 (ru)
CY (1) CY1107388T1 (ru)
CZ (1) CZ20031283A3 (ru)
DE (1) DE60132799T2 (ru)
DK (1) DK1335908T3 (ru)
EA (1) EA006920B1 (ru)
EC (1) ECSP034595A (ru)
ES (1) ES2300378T3 (ru)
HK (1) HK1058790A1 (ru)
HR (1) HRP20030365A2 (ru)
HU (1) HUP0301655A2 (ru)
IL (2) IL154840A0 (ru)
MX (1) MXPA03004141A (ru)
MY (1) MY157884A (ru)
NO (1) NO20032059L (ru)
NZ (1) NZ524569A (ru)
PE (1) PE20020693A1 (ru)
PL (1) PL362692A1 (ru)
PT (1) PT1335908E (ru)
SI (1) SI1335908T1 (ru)
SK (1) SK5412003A3 (ru)
SV (1) SV2003000727A (ru)
TW (1) TW200716572A (ru)
UA (1) UA82048C2 (ru)
WO (1) WO2002038553A2 (ru)
ZA (1) ZA200302517B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043997A1 (en) * 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
JP4675959B2 (ja) 2004-07-27 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルトリアゾロン化合物
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
TW200640453A (en) * 2005-01-28 2006-12-01 Lilly Co Eli Formulations and dosing regimen for PPAR-α modulators
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US20090036489A1 (en) * 2005-03-22 2009-02-05 Masahiro Nomura Novel Cyclic Aminophenylalkanoic Acid Derivative
CA2600759A1 (en) * 2005-03-24 2006-09-28 F. Hoffmann-La Roche Ag 1,2,4-triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
JP5225076B2 (ja) * 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
AU2008218841A1 (en) * 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
CN101657433A (zh) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US8323360B2 (en) * 2008-06-30 2012-12-04 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
EP2380884B1 (en) 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
CA2921420A1 (en) * 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
WO2021205803A1 (ja) 2020-04-10 2021-10-14 パナソニックＩｐマネジメント株式会社 熱電変換素子、熱電変換モジュール、接合材、及び熱電変換素子を製造する方法
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
WO1997015567A1 (de) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
BR9804500B1 (pt) 1997-10-17 2010-06-15 derivado de amida, referida composição farmacêutica e agente terapêutico.
DE69828445D1 (de) * 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
MXPA03004141A (es) 2003-08-19
EP1335908A2 (en) 2003-08-20
UA82048C2 (ru) 2008-03-11
NO20032059L (no) 2003-06-24
AU2859202A (en) 2002-05-21
AU2002228592B2 (en) 2006-04-27
JP4243101B2 (ja) 2009-03-25
HK1058790A1 (en) 2004-06-04
AU2006202811A1 (en) 2006-07-20
PL362692A1 (en) 2004-11-02
US20090062358A1 (en) 2009-03-05
WO2002038553A2 (en) 2002-05-16
US20090044299A1 (en) 2009-02-12
NO20032059D0 (no) 2003-05-08
CA2421154A1 (en) 2002-05-16
US20040102500A1 (en) 2004-05-27
DE60132799D1 (de) 2008-03-27
US7304062B2 (en) 2007-12-04
ZA200302517B (en) 2004-06-30
NZ524569A (en) 2006-05-26
ES2300378T3 (es) 2008-06-16
TW200716572A (en) 2007-05-01
DK1335908T3 (da) 2008-06-02
EA006920B1 (ru) 2006-04-28
KR20030048133A (ko) 2003-06-18
PE20020693A1 (es) 2002-08-05
SV2003000727A (es) 2003-01-13
SI1335908T1 (sl) 2008-08-31
DE60132799T2 (de) 2009-03-19
HUP0301655A2 (hu) 2003-12-29
JP2004513166A (ja) 2004-04-30
SK5412003A3 (en) 2004-01-08
HRP20030365A2 (en) 2003-08-31
ATE386026T1 (de) 2008-03-15
US7868225B2 (en) 2011-01-11
AR031305A1 (es) 2003-09-17
EP1335908B1 (en) 2008-02-13
CY1107388T1 (el) 2012-12-19
AU2002228592B8 (en) 2006-08-24
PT1335908E (pt) 2008-05-08
ECSP034595A (es) 2003-06-25
CZ20031283A3 (cs) 2003-09-17
IL154840A (en) 2009-09-22
IL154840A0 (en) 2003-10-31
CN1479728A (zh) 2004-03-03
MY157884A (en) 2016-08-01
KR100839705B1 (ko) 2008-06-19
WO2002038553A3 (en) 2003-05-01
BR0114986A (pt) 2003-09-23

Similar Documents

Publication Publication Date Title
EA200300558A1 (ru) Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
EA200401431A1 (ru) Производные триазола в качестве антагонистов рецептора тахикинина
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
BRPI0514742A (pt) sintese alternativa de inibidores de renina e intermediários destes
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
DE60130771D1 (de) Substituierte heterocyclische amide
EA200201259A1 (ru) Производные бензимидазола, их получение и терапевтическое применение
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
ES2259113T3 (es) Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion.
EA200201141A1 (ru) Производные тропана, полезные для терапии
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
EA200300064A1 (ru) Карбоксамидные соединения и их применение в качестве антагонистов 11cby-рецептора человека
RS51085B (sr) Derivati dioksan-2-alkilkarbamata, postupak za njihovo dobijanje i primena istih u terapeuticima
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
NO20044063L (no) Pyranoner anvendelige som ATM-inhibitorer
EA200400748A1 (ru) Агонисты рецепторов, активируемых пероксисомным пролифератором
JP2005517643A5 (ru)
DE60327922D1 (de) Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
ATE375350T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU